Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
Research ArticleArticle

The Circulating Cell-free microRNA Profile in Systemic Sclerosis Is Distinct from Both Healthy Controls and Systemic Lupus Erythematosus

Samantha O. Steen, Line V. Iversen, Anting Liu Carlsen, Mark Burton, Christoffer T. Nielsen, Søren Jacobsen and Niels H.H. Heegaard
The Journal of Rheumatology November 2014, jrheum.140502; DOI: https://doi.org/10.3899/jrheum.140502
Samantha O. Steen
From the Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut; Department of Dermatology, Bispebjerg Hospital, and the Department of Rheumatology, Rigshospitalet, University of Copenhagen, Copenhagen; Department of Clinical Genetics, and the Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense; Research Unit of Human Genetics, and Clinical Biochemistry, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark. Supported by the Foundation for the Advancement of Medical Research, Bang’s Foundation, and the Danish Rheumatism Association (R99-A1937). S.O. Steen, MSc; A.L. Carlsen, PhD, Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut; L.V. Iversen, MD, PhD, Department of Dermatology, Bispebjerg Hospital, University of Copenhagen; M. Burton, PhD, Department of Clinical Genetics, Odense University Hospital, and the Institute of Clinical Research, Research Unit of Human Genetics, University of Southern Denmark; C.T. Nielsen, MD, PhD; S. Jacobsen, MD, DMedSc, Department of Rheumatology, Rigshospitalet, University of Copenhagen; N.H.H. Heegaard, MD, DMedSc, DNatSc, Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, and the Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, and the Institute of Clinical Research, Clinical Biochemistry, University of Southern Denmark. Address correspondence to Dr. N. Heegaard, Department of Autoimmunology and Biomarkers, Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen S, Denmark. E-mail: nhe@ssi.dk. Accepted for publication October 1, 2014.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Line V. Iversen
From the Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut; Department of Dermatology, Bispebjerg Hospital, and the Department of Rheumatology, Rigshospitalet, University of Copenhagen, Copenhagen; Department of Clinical Genetics, and the Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense; Research Unit of Human Genetics, and Clinical Biochemistry, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark. Supported by the Foundation for the Advancement of Medical Research, Bang’s Foundation, and the Danish Rheumatism Association (R99-A1937). S.O. Steen, MSc; A.L. Carlsen, PhD, Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut; L.V. Iversen, MD, PhD, Department of Dermatology, Bispebjerg Hospital, University of Copenhagen; M. Burton, PhD, Department of Clinical Genetics, Odense University Hospital, and the Institute of Clinical Research, Research Unit of Human Genetics, University of Southern Denmark; C.T. Nielsen, MD, PhD; S. Jacobsen, MD, DMedSc, Department of Rheumatology, Rigshospitalet, University of Copenhagen; N.H.H. Heegaard, MD, DMedSc, DNatSc, Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, and the Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, and the Institute of Clinical Research, Clinical Biochemistry, University of Southern Denmark. Address correspondence to Dr. N. Heegaard, Department of Autoimmunology and Biomarkers, Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen S, Denmark. E-mail: nhe@ssi.dk. Accepted for publication October 1, 2014.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anting Liu Carlsen
From the Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut; Department of Dermatology, Bispebjerg Hospital, and the Department of Rheumatology, Rigshospitalet, University of Copenhagen, Copenhagen; Department of Clinical Genetics, and the Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense; Research Unit of Human Genetics, and Clinical Biochemistry, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark. Supported by the Foundation for the Advancement of Medical Research, Bang’s Foundation, and the Danish Rheumatism Association (R99-A1937). S.O. Steen, MSc; A.L. Carlsen, PhD, Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut; L.V. Iversen, MD, PhD, Department of Dermatology, Bispebjerg Hospital, University of Copenhagen; M. Burton, PhD, Department of Clinical Genetics, Odense University Hospital, and the Institute of Clinical Research, Research Unit of Human Genetics, University of Southern Denmark; C.T. Nielsen, MD, PhD; S. Jacobsen, MD, DMedSc, Department of Rheumatology, Rigshospitalet, University of Copenhagen; N.H.H. Heegaard, MD, DMedSc, DNatSc, Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, and the Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, and the Institute of Clinical Research, Clinical Biochemistry, University of Southern Denmark. Address correspondence to Dr. N. Heegaard, Department of Autoimmunology and Biomarkers, Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen S, Denmark. E-mail: nhe@ssi.dk. Accepted for publication October 1, 2014.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Burton
From the Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut; Department of Dermatology, Bispebjerg Hospital, and the Department of Rheumatology, Rigshospitalet, University of Copenhagen, Copenhagen; Department of Clinical Genetics, and the Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense; Research Unit of Human Genetics, and Clinical Biochemistry, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark. Supported by the Foundation for the Advancement of Medical Research, Bang’s Foundation, and the Danish Rheumatism Association (R99-A1937). S.O. Steen, MSc; A.L. Carlsen, PhD, Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut; L.V. Iversen, MD, PhD, Department of Dermatology, Bispebjerg Hospital, University of Copenhagen; M. Burton, PhD, Department of Clinical Genetics, Odense University Hospital, and the Institute of Clinical Research, Research Unit of Human Genetics, University of Southern Denmark; C.T. Nielsen, MD, PhD; S. Jacobsen, MD, DMedSc, Department of Rheumatology, Rigshospitalet, University of Copenhagen; N.H.H. Heegaard, MD, DMedSc, DNatSc, Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, and the Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, and the Institute of Clinical Research, Clinical Biochemistry, University of Southern Denmark. Address correspondence to Dr. N. Heegaard, Department of Autoimmunology and Biomarkers, Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen S, Denmark. E-mail: nhe@ssi.dk. Accepted for publication October 1, 2014.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christoffer T. Nielsen
From the Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut; Department of Dermatology, Bispebjerg Hospital, and the Department of Rheumatology, Rigshospitalet, University of Copenhagen, Copenhagen; Department of Clinical Genetics, and the Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense; Research Unit of Human Genetics, and Clinical Biochemistry, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark. Supported by the Foundation for the Advancement of Medical Research, Bang’s Foundation, and the Danish Rheumatism Association (R99-A1937). S.O. Steen, MSc; A.L. Carlsen, PhD, Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut; L.V. Iversen, MD, PhD, Department of Dermatology, Bispebjerg Hospital, University of Copenhagen; M. Burton, PhD, Department of Clinical Genetics, Odense University Hospital, and the Institute of Clinical Research, Research Unit of Human Genetics, University of Southern Denmark; C.T. Nielsen, MD, PhD; S. Jacobsen, MD, DMedSc, Department of Rheumatology, Rigshospitalet, University of Copenhagen; N.H.H. Heegaard, MD, DMedSc, DNatSc, Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, and the Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, and the Institute of Clinical Research, Clinical Biochemistry, University of Southern Denmark. Address correspondence to Dr. N. Heegaard, Department of Autoimmunology and Biomarkers, Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen S, Denmark. E-mail: nhe@ssi.dk. Accepted for publication October 1, 2014.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Søren Jacobsen
From the Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut; Department of Dermatology, Bispebjerg Hospital, and the Department of Rheumatology, Rigshospitalet, University of Copenhagen, Copenhagen; Department of Clinical Genetics, and the Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense; Research Unit of Human Genetics, and Clinical Biochemistry, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark. Supported by the Foundation for the Advancement of Medical Research, Bang’s Foundation, and the Danish Rheumatism Association (R99-A1937). S.O. Steen, MSc; A.L. Carlsen, PhD, Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut; L.V. Iversen, MD, PhD, Department of Dermatology, Bispebjerg Hospital, University of Copenhagen; M. Burton, PhD, Department of Clinical Genetics, Odense University Hospital, and the Institute of Clinical Research, Research Unit of Human Genetics, University of Southern Denmark; C.T. Nielsen, MD, PhD; S. Jacobsen, MD, DMedSc, Department of Rheumatology, Rigshospitalet, University of Copenhagen; N.H.H. Heegaard, MD, DMedSc, DNatSc, Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, and the Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, and the Institute of Clinical Research, Clinical Biochemistry, University of Southern Denmark. Address correspondence to Dr. N. Heegaard, Department of Autoimmunology and Biomarkers, Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen S, Denmark. E-mail: nhe@ssi.dk. Accepted for publication October 1, 2014.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Niels H.H. Heegaard
From the Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut; Department of Dermatology, Bispebjerg Hospital, and the Department of Rheumatology, Rigshospitalet, University of Copenhagen, Copenhagen; Department of Clinical Genetics, and the Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense; Research Unit of Human Genetics, and Clinical Biochemistry, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark. Supported by the Foundation for the Advancement of Medical Research, Bang’s Foundation, and the Danish Rheumatism Association (R99-A1937). S.O. Steen, MSc; A.L. Carlsen, PhD, Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut; L.V. Iversen, MD, PhD, Department of Dermatology, Bispebjerg Hospital, University of Copenhagen; M. Burton, PhD, Department of Clinical Genetics, Odense University Hospital, and the Institute of Clinical Research, Research Unit of Human Genetics, University of Southern Denmark; C.T. Nielsen, MD, PhD; S. Jacobsen, MD, DMedSc, Department of Rheumatology, Rigshospitalet, University of Copenhagen; N.H.H. Heegaard, MD, DMedSc, DNatSc, Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, and the Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, and the Institute of Clinical Research, Clinical Biochemistry, University of Southern Denmark. Address correspondence to Dr. N. Heegaard, Department of Autoimmunology and Biomarkers, Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen S, Denmark. E-mail: nhe@ssi.dk. Accepted for publication October 1, 2014.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • References
  • Info & Metrics
  • PDF
  • eLetters
Next
Loading

Abstract

Objective To evaluate the expression profile of cell-free circulating microRNA (miRNA) in systemic sclerosis (SSc), healthy controls (HC), and systemic lupus erythematosus (SLE).

Methods Total RNA was purified from plasma and 45 different, mature miRNA were measured using quantitative PCR assays after reverse transcription. Samples (n = 189) were from patients with SSc (n = 120), SLE (n = 29), and from HC (n = 40). Expression data were clustered by principal components analysis, and diagnostically specific miRNA profiles were developed by leave-one-out cross-validation. Diagnostic probability scores were derived from stepwise logistic regression.

Results Thirty-seven miRNA specificities were consistently detected and 26 of these were unaffected by SSc sample age and present in more than two-thirds of SSc samples. SSc cases showed a distinct expression profile with 14/26 miRNA significantly decreased (false discovery rate < 0.05) and 5/26 increased compared with HC. A 21-miRNA classifier gave optimum accuracy (80%) for discriminating SSc from both HC and SLE. The discrimination between HC and SSc (95% accuracy) was strongly driven by miRNA of the 17~92 cluster and by miR-16, -223, and -638, while SLE and SSc differed mainly in the expression of miR-142-3p, -150, -223, and -638. Except for a weak correlation between anti-Scl-70 and miR-638 (p = 0.048), there were no correlations with other patient variables.

Conclusion Circulating miRNA profiles are characteristic for SSc compared with both HC and SLE cases. Some of the predicted targets of the differentially regulated miRNA are of relevance for transforming growth factor-β signaling and fibrosis, but need to be validated in independent studies.

Next
Back to top

In this issue

The Journal of Rheumatology
Vol. 48, Issue 3
1 Mar 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Circulating Cell-free microRNA Profile in Systemic Sclerosis Is Distinct from Both Healthy Controls and Systemic Lupus Erythematosus
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Circulating Cell-free microRNA Profile in Systemic Sclerosis Is Distinct from Both Healthy Controls and Systemic Lupus Erythematosus
Samantha O. Steen, Line V. Iversen, Anting Liu Carlsen, Mark Burton, Christoffer T. Nielsen, Søren Jacobsen, Niels H.H. Heegaard
The Journal of Rheumatology Nov 2014, jrheum.140502; DOI: 10.3899/jrheum.140502

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
The Circulating Cell-free microRNA Profile in Systemic Sclerosis Is Distinct from Both Healthy Controls and Systemic Lupus Erythematosus
Samantha O. Steen, Line V. Iversen, Anting Liu Carlsen, Mark Burton, Christoffer T. Nielsen, Søren Jacobsen, Niels H.H. Heegaard
The Journal of Rheumatology Nov 2014, jrheum.140502; DOI: 10.3899/jrheum.140502
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
  • Figures & Data
  • Supplemental
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Composite Measures for Clinical Trials in Psoriatic Arthritis: Testing Pain and Fatigue Modifications in a UK Multicenter Study
  • GRAPPA Patient Research Partner Network: Update to the GRAPPA 2020 Annual Meeting
  • Descriptive Comparisons of the Effect of Apremilast and Methotrexate Monotherapy in Oligoarticular Psoriatic Arthritis: The Corrona Psoriatic Arthritis/Spondyloarthritis Registry Results
Show more Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire